AllPennyStocks.com Revolution Medicine’s $39,800-Monthly Cancer Drug Puts Access In Focus — CEO Goldsmith Expects Insurers To Move ‘Swiftly’ To Provide Coverage
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Revolution Medicine’s $39,800-Monthly Cancer Drug Puts Access In Focus — CEO Goldsmith Expects Insurers To Move ‘Swiftly’ To Provide Coverage

CEO Mark Goldsmith said discussions with insurers gave the company confidence that they understand the drug’s clinical value.

Other Penny Stock Movers

$500 Million AI Merger Sends This Microcap Soaring
Colombian Oil Producer Jumps as Q2 Revenue More Than Doubles
Medtech Developer Surges on Triple-Digit EBITDA Growth
Most Popular
{{ index + 1 }}
AllPennyStocks.com Favorites


Back to Top